One type of androgen deprivation therapy may speed coronary plaque growth in men being treated for localized prostate cancer.
Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," ...
MedPage Today on MSN
Two Types of ADT for Prostate Cancer, Different Effects on Coronary Artery Plaque
Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...
The REVELUTION (Relugolix versus Leuprolide Cardiac) trial compared coronary plaque after 2 types of androgen deprivation therapy (ADT) for prostate cancer.
The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival ...
"There is no evidence that ADT followed by brachytherapy increases the chance of cure in comparison to other treatments, such an external beam radiation therapy alone, in these men with favorable risk ...
New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients ...
News-Medical.Net on MSN
Combination therapy may help overcome barrier in early-stage prostate cancer treatment
A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help ...
Metastasis-directed therapy added to ADT helps slow the progression of metastatic prostate cancer, a phase 2 trial finds. The addition of metastasis-directed therapy (MDT) to androgen deprivation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results